Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off
Novartis AG (NYSE:NVS) has reported Q4 core EPS of $1.52 compared to $1.40 a year ago, beating the consensus of $1.44.…
Novartis Q4 Core EPS $1.52 Beats $1.44 Estimate, Sales $12.69B Miss $13.13B Estimate
Novartis (NYSE:NVS) reported quarterly earnings of $1.52 per share which beat the analyst consensus estimate of $1.44 by 5.56 percent. This is a 8.57 percent increase over earnings of $1.40 per share from the same period
A Preview Of Novartis’s Earnings
Novartis (NYSE:NVS) is set to give its latest quarterly earnings report on Wednesday, 2023-02-01. Here’s what investors need…
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.
Analyst Views Novo Nordisk’s Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly’s Tirzepatide
Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.
Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units
Novartis AG (NYSE: NVS) said it would narrow its focus on five core therapeutic areas, including cardiovascular, immunology, neurodegenerative diseases, solid tumors, and hematology.
Traders Circulate Post Suggesting Novartis AG ‘Misses On 2nd Interim For NATALEE Trial. Not A Good Sign For Differentiation Vs Abema’
https://twitter.com/pharmacreep/status/1612487217800167424